GentiBio

GentiBio is a biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune allergic diseases.

The early-stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complementary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.

GentiBio is a Seattle, Washington-headquartered company launched in 2020 by Adel Nada, Chandra Patel, and Andy Walker.

GentiBio headquartered in United States, North America, operates in the Biotechnology, Life Science sector. The company focuses on Biotechnology and has secured $2.8B in funding across 16 round(s). With a team of 51-100 employees, GentiBio is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - GentiBio, raised $157.0M. Discover more about their projects, partnerships, and impact on our platform.